Agreement revolves around Factor VIII purification.

BAC and GE Healthcare will together develop and market affinity chromatography media for the purification of therapeutic recombinant Factor VIII.

BAC will provide its CaptureSelect® affinity ligands for  process-scale purification of FVIII for the prevention and treatment of bleeding in patients with haemophilia A.

Previous articleStreamlining Biomarker Validation Activities
Next articlePfizer Obtains Licence from Genencor to Aid in Protein-Based Drug Development